

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.8362 - LONZA GROUP / CAPSUGEL

SECTION 1.2

Description of the concentration

On 17 March 2017, the European Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No. 139/2004, by which Lonza Group AG (Lonza) intends to acquire sole control over Capsugel S.A. (Capsugel) through a share acquisition.

Lonza is listed on the SIX Swiss Exchange and headquartered in Switzerland. Lonza is a company active in the supply of various services from research to final product manufacturing in the pharmaceutical, health care and life science industries worldwide. It is also active in the manufacture and development of active ingredients for use in the agricultural sector, surface protection in various industries, and water treatment.

Capsugel designs, develops and manufactures a range of dosage forms for the pharmaceutical and nutrition industries. Capsugel's products include oral dosage delivery products, including hard gelatine, soft gelatine, liquid and alternative polymer capsules."